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Abstract Epidemiological studies suggest that individuals
differing in the expression of allelic variants of the human
glutathione transferase (GST) Pi gene differ in susceptibility to
chemical carcinogens such as polycyclic aromatic hydrocarbons
(PAH). This study reports the catalytic efficiencies (kcat/Km) of
two naturally occurring variants, GSTP1-1/I-105 and GSTP1-1/
V-105, towards a series of fjord-region diol epoxides representing
potent biologically active PAH metabolites, and two GSTP1-1
mutants with Ala105 and Trp105 in the active site. The results
indicate that individuals who are homozygous for the allele
encoding GSTP1-1/V-105 might be more susceptible to PAH
carcinogenesis due to other reasons than a reduced capacity for
detoxifying diol epoxides.
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1. Introduction
Polycyclic aromatic hydrocarbons (PAH) are environmental
pollutants and highly suspected as carcinogens in humans
[1,2]. Following their metabolic activation to diastereomeric
bay- and fjord-region diol epoxides, the mutagenic and carci-
nogenic activities appear to be linked to the covalent binding
of these reactive intermediates to the exocyclic amino group of
deoxyguanosine (dG) and deoxyadenosine (dA) in DNA [3^
5].
Available information indicates that fjord-region diol epox-
ides in general are more biologically potent than bay-region
diol epoxides [6]. The former intermediates demonstrate a
higher preference for adduct formation with dA than bay-
region diol epoxides [7,8], which in part may explain the in-
creased potency. Furthermore, whereas the (+)-anti-enantiom-
ers of the bay-region diol epoxides with R,S,S,R-absolute con-
¢guration seem to be the principal tumor initiators among the
four possible stereoisomers, both the anti- and syn-stereoisom-
ers of the fjord-region diol epoxides demonstrate high muta-
genic and/or tumorigenic activity [9,10]. The diequatorial ori-
entation of the hydroxyl groups in all fjord-region diol
epoxides due to the non-planarity and the steric hindrance
in the molecule are likely part of the explanation [9,10].
The most important intracellular system preventing the for-
mation of diol epoxide-DNA adducts is glutathione transfer-
ase (GST)-catalyzed conjugation of the intermediates with
glutathione (GSH) [11]. In this context the Pi class of GSTs
seems to be of particular importance [12,13] and recently it
was demonstrated that GSTPi gene deleted mice exhibit an
increased susceptibility to PAH-induced tumors [14]. In hu-
mans, an allelic variant with Val105 (GSTP1-1/V-105) rather
than Ile105 (GSTP1-1/I-105) has been associated with higher
tumor susceptibility in organs exposed to PAH [15]. In anoth-
er study Matthias et al. [16] showed that the frequency of
GSTP1*A (encoding GSTP1-1/V-105) in individuals with
squamous carcinomas of the upper aerodigestive tract was
lower than in control individuals. Harris et al. [17] recently
examined individuals with colorectal or lung cancer but found
no signi¢cant associations between a particular GSTP1-1 var-
iant and either form of tumor. Thus, the results to date on
GSTP1-1 polymorphism and cancer susceptibility are variable
and further evaluation in larger populations seems to be
needed.
Previous studies have shown that the GSTP1-1/I-105 and
GSTP1-1/V-105 exhibit di¡erent catalytic e⁄ciencies towards
bay-region diol epoxides. With most compounds examined
GSTP1-1/V-105 was more e⁄cient than GSTP1-1/I-105
[18,19]. In organs in which tumor formation is initiated by
DNA adducts derived from bay-region diol epoxides this dif-
ference may be a signi¢cant factor in tumor susceptibility.
Fjord-region diol epoxides are considerably more carcinogenic
in experimental animals and may pose a higher risk as tumor
initiators in humans. Therefore, it is important to evaluate the
role of their GST-catalyzed detoxication. In this study the
catalytic e⁄ciencies of the two naturally occurring GSTP1-1
allelic variants, GSTP1-1/I-105 and GSTP1-1/V-105, towards
several of these compounds have been determined. The meta-
bolically most relevant (3)-anti- and (+)-syn-diol epoxide ster-
eoisomers from benzo[c]phenanthrene (B[c]Ph), benzo[c]chry-
sene (B[c]C), benzo[g]chrysene (B[g]C) and dibenzo[a,l]pyrene
(DB[a,l]P), the most carcinogenic PAH yet identi¢ed [20,21],
have been investigated.
As part of the active site of GSTP1-1 the side-chain of the
amino acid residue in position 105 appears to in£uence cata-
lytic e⁄ciency. To gain insight into the steric requirements for
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e⁄cient catalysis of fjord-region diol epoxides conjugation,
mutants with Ala105 (GSTP1/A-105) or Trp105 (GSTP1-1/W-
105) at this position have also been studied.
2. Materials and methods
2.1. Chemicals
Synthesis of the optically active syn-and anti-diol epoxides of B[c]Ph
[(3)-anti- and (+)-syn-B[c]PhDE], B[c]C [(3)-anti- and (+)-syn-
B[c]CDE], B[g]C [(3)-anti- and (+)-syn-B[g]CDE] and DB[a,l]P
[(3)-anti- and (+)-syn-DB[a,l]PDE] was performed as previously de-
scribed [22^24]. Chromatographic standards of derivatives of
B[c]PhDE, B[c]CDE and B[g]CDE were obtained as previously de-
scribed [22,25]. A similar procedure was used to obtain standard de-
rivatives of DB[a,l]PDE. In brief, GSH conjugates were prepared by
incubating each diol epoxide isomer with a 10 000-fold excess of GSH
in Na2CO3-saturated water (pH = 8.5) and N2 followed by removal of
unreacted diol epoxide and hydrolysis products by ethyl acetate ex-
traction. Tetraols were obtained by hydrolysis of the diol epoxides in
diluted HCl and conjugates with 2-mercaptoethanol by reacting the
diol epoxides with a 5000-fold excess of 2-mercaptoethanol in aqueous
NaOH. All incubations were carried out at ambient temperature and
for at least 12 h. The derivatives of DB[a,l]PDE were subsequently
puri¢ed by HPLC using the conditions described below.
2.2. Glutathione transferases
The GSTP1-1 variants were produced and treated prior to the ex-
periments as recently described [19]. The speci¢c activities of 98, 59,
37 and 56 Wmol CDNB/mg/min were used to calculate the amount of
active protein of GSTP1-1 variants I-105, V-105, A-105, and W-105,
respectively.
2.3. Incubations
Enzyme corresponding to 10^500 Wg active protein/ml was incu-
bated at 37‡C for 1 min with 40 and 80 WM diol epoxide (added in
dimethylsulfoxide, ¢nal concentration 5%, v/v) and 5 mM GSH in 50
mM Tris-HCl bu¡er, pH 7.5 (¢nal volume 100 Wl) and the GSH
conjugates by HPLC as described [22]. The HPLC analysis of GSH
conjugates analyzed of DB[a,l]PDE was performed in principle as
described [22]. In brief, an analytical column (Nova Pak 4Wm C18,
3.9U150 mm, Waters Inc.) and a solvent system composed of 25 mM
ammonium acetate/acetic acid, pH 3.5 (solvent A) in acetonitrile (sol-
vent B) delivered at a £ow rate of 1 ml/min. The following solvent
composition was used: 20^30% B linear gradient for 10 min and 30^
60% B linear gradient for 20 min. The e¥uent was monitored by UV
absorbance at 290 nm. The identities of the peaks were determined by
comparison with standard derivatives. The quantitation of GSH con-
jugates was performed by comparison with authentic standard con-
jugates and using the determined extinction coe⁄cients for the con-
jugates of B[c]PhDE, B[c]CDE and B[g]CDE [22]. For the
quantitation of GSH conjugates of DB[a,l]PDE the extinction coe⁄-
cients of the parent syn- (O294 = 34 000 cm2/mmol) and anti-
DB[a,l]PDE (O295 = 36 500 cm2/mmol) were used. As shown for other
diol epoxides [22] the HPLC procedure employed for the analysis of
DB[a,l]PDE derivatives permits separation of tetraols and 2-mercap-
toethanol conjugates in addition to the separation of diastereomeric
GSH conjugates, thus allowing calculation of total product recovery.
3. Results and discussion
Recent studies have identi¢ed a polymorphism in the hu-
man GSTP1-1 gene which results in three variant protein
products. These are Ile or Val at position 105 and Ala at
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Fig. 1. Structure and numbering system of the fjord-region PAHs from which the diol epoxides used in this study are derived. The absolute
stereochemistry of the syn- and anti-diol epoxides is shown to the right. The pre¢x syn indicates that the oxirane ring and the benzylic hydroxyl
group are located on the same face of the molecule whereas anti indicates location of these groups on opposite faces.
K. Sundberg et al./FEBS Letters 438 (1998) 206^210 207
position 114 (GSTP1-1/I-105 and GSTP1-1/V-105, respec-
tively), and Val at both position 105 and 114 [26^29]. Position
105 is an integral part of the second substrate binding site (the
H-site) of the enzyme whereas position 114 is not [30]. It has
been shown previously that the allelic variants di¡er in their
catalytic activity towards (+)-anti-BPDE, an ultimate carcino-
genic metabolite of benzo[a]pyrene, and other carcinogenic
bay-region diol epoxides [18,19,31]. GSTP1-1/V-105, which
is the less common variant in the human population, demon-
strates a higher catalytic e⁄ciency than GSTP1-1/I-105 to-
wards most of the diol epoxides studied up to now. As with
GSTP1-1/I-105, the GSTP1-1/V-105 variant demonstrates an
almost exclusive preference for the diol epoxide isomers with
R-absolute con¢guration of the benzylic oxiranyl carbon
[18,19]. Interestingly, in both the syn- and the anti-series these
intermediates are more mutagenic and/or carcinogenic than
the corresponding diol epoxide enantiomers with S-absolute
con¢guration [10,33]. P1-1 is the dominating GST isoform in
extrahepatic tissues such as the respiratory and digestive tract,
skin and urinary bladder, all tumor-susceptible organs in
which PAH may play a role in tumor initiation [34].
Recent epidemiological data indicate that individuals ex-
pressing the GSTP1-1/V-105 variant may be more susceptible
to tumor formation in organs exposed to PAH [15^17,35,36].
As discussed recently [19] the elevated activity of GSTP1-1/V-
105 relative to GSTP1-1/I-105 towards carcinogenic bay-re-
gion diol epoxides suggests that the correlation between the
GSTP1*B allele and a higher risk for PAH-induced carcino-
genesis is not due to a lower catalytic e⁄ciency of the corre-
sponding GST. This may have a number of alternative ex-
planations. One possibility is that bay-region diol epoxides
are not the most important tumor initiators in the organs
believed to be susceptible to PAH exposure but rather the
more potent fjord-region analogues. Thus in this study the
catalytic e⁄ciency (kcat/Km) of GSTP1-1/I-105 and GSTP1-
1/V-105 towards the highly mutagenic and carcinogenic
fjord-region anti- and syn-diol epoxides of B[c]Ph, DB[a,l]P,
B[c]C and B[g]C (see Fig. 1 for structures) have been com-
pared. The investigation was restricted to the stereoisomers
with R-absolute con¢guration at the benzylic oxiranyl carbon
because a high degree of stereoselectivity exists in the meta-
bolic activation pathway favoring the formation of isomers
with this stereochemistry and previous work with bay-region
diol epoxides clearly demonstrated that GSTP1-1 exclusively
catalyzes the reaction of these enantiomers with GSH [32].
Finally, the assumption was made that both allelic GSTP1-1
variants are identical in this latter respect.
Measuring conjugates of diol epoxides with GSH includes
brief incubation of enzyme, GSH and the second substrate
followed by addition of alkaline mercaptoethanol to trap un-
reacted diol epoxide. Reaction products were subsequently
estimated by HPLC. Fig. 2A,B shows the results obtained
with the (3)-anti- and (+)-syn-DB[a,l]PDE and GSTP1-1/A-
105. As is evident from Fig. 2 the reaction products are chro-
matographically well resolved including the diastereomeric
GSH conjugates (Rt = 8 and 12 min, respectively in A and B).
Position 105 in GSTP1-1 is part of the second substrate
binding site (H-site) and recent results with bay-region anti-
diol epoxides demonstrated a reciprocal correlation between
the bulkiness (Trps IlesValsAla) of the amino acid resi-
due at this position and the catalytic e⁄ciency kcat/Km. With
the bay-region syn-diol epoxides a gradual reduction in kcat/
Km was observed with the Ala105, Val105, and Ile105 variants
but not with the Trp105 variant. In fact, the introduction of
Trp105 substantially increased the activity [19].
The kcat/Km values obtained with all fjord-region diol epox-
ides and GSTP1-1 variants employed are compiled in Table 1.
From these and previous results [22,25,31] it can be concluded
that fjord-region diol epoxides are inferior as substrates for
GSTP1-1 relative to most of the bay-region diol epoxides
studied. Focusing on the results obtained with GSTP1-1/V-
105 and GSTP1-1/I-105 it can be concluded that both variants
demonstrate a similar activity towards each anti enantiomer
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Fig. 2. HPLC elution pro¢le of products derived from (3)-anti-
DB[a,l]PDE (A) and (+)-syn- DB[a,l]PDE (B). DE-SG: glutathione
conjugate of the corresponding diol epoxide. T1 and T2: the tet-
raols resulting from hydrolytic trans and cis opening of the epoxide.
DE-SEtOH: 2-mercaptoethanol conjugate of the corresponding diol
epoxide.
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but di¡er towards the syn enantiomers. In this case GSTP1-1/
V-105 is about 2^3-fold more active. As observed with the
bay-region diol epoxides [19] the e¡ect of gradually increasing
the bulkiness of the amino residue at position 105 from Ala to
Trp was dependent on the diol epoxide diastereomer studied.
With the (3)-anti enantiomers, GSTP1-1/A-105 was generally
the most active variant whereas GSTP1-1/W-105 showed the
lowest activity. With the (+)-syn enantiomers, on the other
hand, GSTP1-1/W-105 was in most cases equally active as
or more active than GSTP1-1/A-105. Taking these and earlier
results for bay-region diol epoxides together, the inhibiting
e¡ect of increasing the volume of the amino acid residue at
position 105 on kcat/Km for the fjord-region analogues is prob-
ably due to disturbance of the hydrophobic/hydrophilic bal-
ance in the active site in conjunction with a more restricted
binding site for the diol epoxide [18,19].
The reason for the high activity towards the syn enantiom-
ers of both bay- and fjord-region diol epoxides in comparison
with the anti enantiomers is still unclear. A factor expected to
in£uence the activity is the preferred conformation of the
hydroxyl groups of the diol epoxide. In the syn diastereomers
of the bay-region diol epoxides a pseudo-axial orientation is
preferred whereas a pseudo-equatorial orientation is preferred
in the corresponding diastereomers of the more crowded
fjord-region diol epoxides. Assuming that the spatial orienta-
tion of the hydroxyl groups remains the same when bound to
the active site of the enzyme, the conformation of the syn-diol
epoxides seems to play a minor role for the rate of GSTP1-1/
W-105-catalyzed S-glutathionylation. However, the absolute
con¢guration of the hydroxyl groups of the diol epoxides
seems to be important. Since all GSTP1-1 variants demon-
strate a high preference for S-glutathionylation at the benzylic
oxiranyl carbon with R-absolute con¢guration the R,S-con¢g-
uration of the hydroxyl groups in the anti-diol epoxides re-
sults in reduced activity with GSTP1-1/W-105 whereas the
S,R-con¢guration in the syn forms leads to an enhanced ac-
tivity.
In conclusion, the data obtained with the strongly carcino-
genic fjord-region diol epoxides demonstrate an equal ca-
pacity of GSTP1-1/V-105 and GSTP1-1/I-105 to detoxify
(3)-anti enantiomers and an increased activity of the Val105
variant to conjugate the (+)-syn enantiomers with GSH. These
results together with those observed with the bay-region diol
epoxides indicate that individuals who are homozygous for
the allele encoding GSTP1-1/V-105 are more susceptible to
carcinogenesis due to other reasons than a reduced capacity
for detoxifying diol epoxides. Nevertheless, the data show that
GSTP1-1-catalyzed conjugation is e⁄cient and therefore an
important inactivation mechanism of the highly carcinogenic
fjord-region diol epoxides.
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